SARS-CoV-2 Spike RBD Monoclonal Antibody
$375.00
Monoclonal SARS-CoV-2 spike antibody as the human IgG antibody positive control for serological assays for qualitative detection or semi-quantitative measurement of human IgG antibodies specific to the SARS-CoV-2 spike protein, S1 subunit in serum or plasma.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | |
|---|---|
| Product Name | SARS-CoV-2 Spike RBD Monoclonal Antibody |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
Description
PA007140: SARS-CoV-2 Spike RBD Monoclonal Antibody (Clone # CR3022)
Human IgG Monoclonal Antibody.
The monoclonal SARS-CoV-2 (2019-nCoV) spike antibody (S protein antibody, spike S1 antibody) was produced in mammalian cells.
Specificity/Sensitivity: The monoclonal SARS-CoV-2 (2019-nCoV) spike RBD antibody binds to SARS-CoV-2 and SARS-CoV spike RBD, S protein, and S1 subunit.
Applications: ELISA 1:10000, Flow Cytometry 1:500. It might be used as the human IgG antibody positive control for serological assays to detect SARS-CoV and SARS-CoV-2 infection.
Form of Antibody: 1 mg/ml in PBS, pH 7.4.
Clone: CR3022.
Isotype: hIgG1, H+L.
Purity: >95% by SDS-PAGE under reducing conditions.
Shipping: The monoclonal SARS-CoV-2 spike RBD antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Please ask for a quote if you need the recombinant spike RBD monoclonal antibody as the human IgM antibody positive control for serological assays. To check more Syd Labs SARS-CoV-2 (2019-nCoV) Antigen and Antibody Reagents and Discovery Services
Background
The receptor binding domain (RBD) in the S1 subunit of the SARS-CoV-2 (2019-nCoV) spike (S) glycoprotein plays the most important roles in viral attachment, fusion and entry. The SARS-CoV and SARS-CoV-2 S proteins mediate viral entry into host cells by binding to a host receptor, angiotensin-converting enzyme 2 (ACE2), through the receptor-binding domain (RBD) in the S1 subunit, and then fusing the viral and host membranes through the S2 subunit. The ACE2-binding affinity of the Spike RBD of SARS-CoV-2 is 10- to 20-fold higher than that of SARS-CoV.
The SARS-CoV-2 S protein, especially its S1 subunit and RBD, has become a popular target of antibodies for diagnostics test, and proteins and antibodies for therapeutic drugs. The amino-acid sequence identity is around 74% between the RBDs in the SARS-CoV and SARS-CoV-2 S proteins, similar to the 77% identity between the whole S proteins of SARS-CoV and SARS-CoV-2. Such a high degree of sequence similarity raises the possibility that cross-reactive epitopes may exist. Although the SARS-CoV RBD polyclonal antibodies can recognize both viruses, only one out of a few published RBD monoclonal antibodies neutralizing SARS-CoV binds to SARS-CoV-2 spike RBD. Out of the 28 residues in the epitope of the S1 RBD monoclonal antibody, only 4 residues (14%) in SARS-CoV-2 S1 RBD are different from those in SARS-CoV S1 RBD. However, the S1 RBD mAb binds to SARS-CoV spike RBD (Kd = 1 nM) with a much higher affinity than to SARS-CoV-2 spike RBD (Kd = 115 nM, or 6.3 nM measured by another lab). It remains unreported that the S1 RBD neutralizing monoclonal antibody from a recovered SARS patient also behaves as a neutralizing antibody of SARS-CoV-2.
Frequent questions related to “SARS-CoV-2 Spike RBD Monoclonal Antibody”:
Popular searches related to “SARS-CoV-2 Spike RBD Monoclonal Antibody”:
Additional information
| Ship from Country | USA |
|---|---|
| Size | 500 ug |
